SHPH · XBRL financial data

Shuttle Pharmaceuticals Holdings financial statements, every fiscal year

The same tables from 5 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (SHPH's year ends in late December)

In thousands of dollars	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024†Dec 31, 2024	FY 2025Dec 31, 2025
Research and development	1,489	3,517	3,619	4,055
General and administrative	199	1,047	1,393	5,673
Total operating expenses	2,554	5,892	7,696	11,917
Operating income (loss)	(2,554)	(5,892)	(7,696)	(11,917)
Interest income	—	79	38	1
Interest expense	918	2,123	—	—
Net income (loss)	(3,028)	(6,593)	(9,145)	(11,722)
Earnings per share, basic USD per share	(0.29)	(3.53)	(3.19)	(7.16)
Earnings per share, diluted USD per share	(5.04)	(3.53)	(3.30)	(7.16)
Weighted average shares, basic thousands of shares	10,351	1,866	2,870	1,638
Weighted average shares, diluted thousands of shares	1,338	1,866	2,887	1,638

† Share count changed about 1/4 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (SHPH's year ends in late December)

In thousands of dollars	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024†Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	8,417	2,576	1,920	334
Marketable securities	—	2,887	—	—
Prepaid and other current assets	—	—	291	169
Total current assets	8,578	5,593	2,211	503
Property and equipment, net	13	25	19	17
Right-of-use asset	56	334	276	102
Total assets	8,654	5,952	2,506	10,476
Total current liabilities	976	1,042	1,534	7,967
Total deposits	—	6	—	—
Lease liability, non-current	—	304	238	155
Total liabilities	976	1,896	1,797	8,222
Accumulated deficit	(8,895)	(25,433)	(34,578)	(46,300)
Total stockholders' equity	7,678	4,056	709	2,254
Total liabilities and equity	8,654	5,952	2,506	10,476
Common shares outstanding (cover page) thousands of shares	13,654	16,795	4,077	5,591

† Share count changed about 1/4 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (SHPH's year ends in late December)

In thousands of dollars	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024†Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(3,028)	(6,593)	(9,145)	(11,722)
Stock-based compensation	404	182	260	933
Net cash from operating activities	(2,710)	(5,581)	(7,327)	(9,482)
Purchases of property and equipment	—	19	—	—
Net cash from investing activities	—	(2,830)	2,916	(3,057)
Proceeds from issuing common stock	10,022	—	3,993	—
Repayments of long-term debt	—	—	60	—
Net cash from financing activities	10,623	2,570	3,755	10,952
Net change in cash	7,912	(5,841)	(656)	(1,586)

† Share count changed about 1/4 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Shuttle Pharmaceuticals Holdings	90	not reported	(568)*	4.8M	0.2 quarters	Q2 FY26 10-QJun 30, 2026
Aspira Women's Health	477	17	(2,010)*	46.6M	0.2 quarters	Q2 FY26 10-QJun 30, 2026
Creative Medical Technology Holdings	8,714	0	(1,472)*	6.6M	5.9 quarters	Q2 FY26 10-QJun 30, 2026
Target Group	14	1,381	(223)*	617.0M	0.1 quarters	Q2 FY26 10-QJun 30, 2026
Soligenix	9,811	not reported	(1,707)*	21.8M	5.7 quarters	Q2 FY26 10-QJun 30, 2026
Viskase Holdings	7,747	95,279	454*	14.3M	—	Q3 FY26 10-QSep 30, 2026
Matinas BioPharma Holdings	761	not reported	(1,836)*	14.7M	0.4 quarters	Q2 FY26 10-QJun 30, 2026
Xenetic Biosciences	6,472	661	(875)*	2.3M	7.4 quarters	Q2 FY26 10-QJun 30, 2026
Synlogic	13,183	0	(922)*	12.2M	14.3 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.